TAC新辅助化疗方案治疗三阴性乳腺癌的疗效及预后

【摘要】目的 探讨TAC新辅助化疗方案治疗三阴性乳腺癌（triple-negative breast cancer，TNBC）的临床疗效。方法 对接受4～6个周期TAC新辅助化疗方案治疗的63例TNBC进行回顾性研究，分析近远期化疗疗效。结果 63例患者总有效率(RR)96.83%，其中完全缓解(CR)57.14%（36/63)，部分缓解(PR)39.68%(25/63）。主要不良反应中性粒细胞减少36例（57.14%），中性粒细胞减少性发热25例（39.68%），恶心呕吐33例（52.38%），腹泻14例（22.22%），口腔黏膜炎13例（20.63%），乏力虚弱10例（15.87%）。术后死亡7例，局部复发8例，远处转移21例，3年生存率88.89%。结论 应用TAC新辅助化疗方案能提高TNBC治疗效果，改善患者生活质量，提高3年生存率。

Curative effect of TAC neoadjuvant chemotherapy on patients with triple negative breast cancer

Objective To investigate the effect of neoadjuvant chemotherapy of TAC in the treatment of triple-negative breast cancer.Methods From Jan 2006 to Jan,sixty-three patients with triple-negative breast cancer received 4-6 cycles of TAC neoadjuvant chemotherapy.The clinical data of 63 cases were retrospectively investigated the near-term and long-term curative effects.Results Of the 63 patients,the overal response rate(RR) was 96.83%,including complete response(CR) 57.14%(36 /63),partial response(PR)39.68%(25 /63).The major complications included neutropenia(57.14%),nertropenia associated fever(39.68%),nausea and vomiting(52.38%),diarrhea(22.22%),oral mucositis(20.63%),malaise and weakness(15.87%).Postoperative death was in 7 cases.There were 8 cases of local recurrence and 21 cases of remote metastasis.The overall 3-year survival rate was 88.89%.Conclusion TAC neoadjuvant chemotherapy could improve the curative effect of TNBC with better quality of life and promoted 3-year survival rate.